BRPI0717943A2 - Composição farmacêutica; forma de dosagem farmacêutica; processo para a preparação de uma composição farmacêutica; e produto preparado pelo processo - Google Patents

Composição farmacêutica; forma de dosagem farmacêutica; processo para a preparação de uma composição farmacêutica; e produto preparado pelo processo

Info

Publication number
BRPI0717943A2
BRPI0717943A2 BRPI0717943-0A2A BRPI0717943A BRPI0717943A2 BR PI0717943 A2 BRPI0717943 A2 BR PI0717943A2 BR PI0717943 A BRPI0717943 A BR PI0717943A BR PI0717943 A2 BRPI0717943 A2 BR PI0717943A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical
preparing
dosage form
product prepared
Prior art date
Application number
BRPI0717943-0A2A
Other languages
English (en)
Inventor
Mannching Sherry Ku
France Anne Donahue
Eugene Lee
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0717943A2 publication Critical patent/BRPI0717943A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0717943-0A2A 2006-10-31 2007-10-30 Composição farmacêutica; forma de dosagem farmacêutica; processo para a preparação de uma composição farmacêutica; e produto preparado pelo processo BRPI0717943A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85566306P 2006-10-31 2006-10-31
PCT/US2007/082966 WO2008055136A2 (en) 2006-10-31 2007-10-30 Liquid formulations of phospholipase enzyme inhibitors

Publications (1)

Publication Number Publication Date
BRPI0717943A2 true BRPI0717943A2 (pt) 2013-10-29

Family

ID=39345039

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717943-0A2A BRPI0717943A2 (pt) 2006-10-31 2007-10-30 Composição farmacêutica; forma de dosagem farmacêutica; processo para a preparação de uma composição farmacêutica; e produto preparado pelo processo

Country Status (10)

Country Link
US (1) US20100113443A1 (pt)
EP (1) EP2104498A2 (pt)
JP (1) JP2010508302A (pt)
AR (1) AR063743A1 (pt)
AU (1) AU2007313706A1 (pt)
BR (1) BRPI0717943A2 (pt)
CL (1) CL2007003143A1 (pt)
PE (1) PE20081408A1 (pt)
TW (1) TW200824712A (pt)
WO (1) WO2008055136A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2614144B1 (en) 2010-09-08 2015-07-22 Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
GB201401904D0 (en) 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6352718B1 (en) * 1999-09-27 2002-03-05 American Cyanamid Company Vasopressin antagonist formulation and process
IL160761A0 (en) * 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
US6984735B2 (en) * 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6797708B2 (en) * 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US7605156B2 (en) * 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US20050002158A1 (en) * 2002-02-25 2005-01-06 Robert Olodort Mobile computer with foldable keyboard
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7582771B2 (en) * 2003-09-03 2009-09-01 Wyeth Process for the synthesis of cPLA2 inhibitors
US7342119B2 (en) * 2003-09-30 2008-03-11 Wyeth Holdings Corporation Process for the synthesis of a CPLA2 inhibitor
JP2007515403A (ja) * 2003-11-17 2007-06-14 ワイス Ｎ−置換フタルイミドの調製方法
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AR048239A1 (es) * 2004-02-25 2006-04-12 Wyeth Corp Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo e intermediarios de sintesis de los mismos
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
TW200718687A (en) * 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2

Also Published As

Publication number Publication date
EP2104498A2 (en) 2009-09-30
WO2008055136A3 (en) 2009-07-23
CL2007003143A1 (es) 2008-01-25
JP2010508302A (ja) 2010-03-18
WO2008055136A2 (en) 2008-05-08
AU2007313706A1 (en) 2008-05-08
US20100113443A1 (en) 2010-05-06
AR063743A1 (es) 2009-02-18
PE20081408A1 (es) 2008-11-04
TW200824712A (en) 2008-06-16

Similar Documents

Publication Publication Date Title
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
BRPI0905847A2 (pt) "composição farmacêutica injetável e processo para preparar a composição"
BRPI0915803A2 (pt) processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica, e, inalador
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BRPI0821676A2 (pt) Composto, composição farmacêutica, e, processo para a preparação dos compostos.
BRPI0816513A2 (pt) Composição farmacêutica e método para preparar a suspensão sólida
BRPI0818541A2 (pt) Processo para a produção de um produto farmacêutico
PT2799089T (pt) Processo para produzir uma formulação farmacêutica de agentes de contraste
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0607423A2 (pt) forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
FI20070569A0 (fi) Uusi stabiili tuote ja menetelmä sen valmistamiseksi
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BR112012004864A2 (pt) composição particulada , processo para produzir uma composição particulada, e , material pulverulento
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
BRPI1007211A2 (pt) composição farmacêutica oral em uma forma sólida, e, processo para preparar uma composição.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
SG151172A1 (en) 1,2,4,5-tetrahydro-3h-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them
BRPI0819534A2 (pt) Composição farmacêutica, método para tratar hiv ou aids e método para preparar uma composição farmacêutica, forma de dosagem e composição"
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
CL2007000680A1 (es) Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc.
SI2030612T1 (sl) Farmacevtski sestavek za zdravljenje opeklin in postopek za njegovo izdelavo
BRPI1016109A2 (pt) "composto, composição farmacêutica, e, processo para preparar um composto"

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]